Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881166 · ClinicalTrials.gov registry record · Phase 1
Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT00881166: Completed Phase 1 study, sponsored by Astex Pharmaceuticals.
NCT00881166 is a Phase 1 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 101 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00881166, a Phase 1 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing regimen will be enrolled in each treatment arm. Primary objective: Determine the MTD. Secondary objectives: Response rates, PK, quantify MP-470 on PK of SOC, and collect pharmacodynamic information. Evaluate the overall safety of MP-470 when co-administered with specific SOC treatments.
Interventions
- DRUG MP-470 + topotecan
- DRUG MP-470 + docetaxel
- DRUG MP-470 + erlotinib
- DRUG MP-470 + paclitaxel/carboplatin
- DRUG MP-470 + carboplatin/etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
What the finished NCT00881166 record still lists
NCT00881166 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% higher).
The record links to 0 conditions, and to 5 interventions - of which MP-470 + topotecan is the first listed.
NCT00881166 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00881166 about?
NCT00881166 is a clinical study titled "Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors". Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing regimen will be enrolled in each treatment arm. Primary objective: Determine the MTD. Secondary objectives: Respons...
What is the current status of trial NCT00881166?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2007-11. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00881166?
The interventions under investigation include: MP-470 + topotecan (DRUG), MP-470 + docetaxel (DRUG), MP-470 + erlotinib (DRUG), MP-470 + paclitaxel/carboplatin (DRUG), MP-470 + carboplatin/etoposide (DRUG).
Who is sponsoring clinical trial NCT00881166?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00881166's enrollment target sits among peer trials
101 546th of 2000 higher than 1,455 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia